|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2009-1-16
|
|
pubmed:abstractText |
Novel drugs including targeted approaches have changed treatment paradigms for multiple myeloma (MM) and may also have therapeutic potential in the poor-prognosis t(4;14) subset; t(4;14) results in overexpressed and activated fibroblast growth factor receptor 3 (FGFR3). Blocking this receptor tyrosine kinase (RTK) induces apoptosis in t(4;14)+ MM cells and decreases adhesion to bone marrow stromal cells (BMSC). Using combinations of novel drugs, we investigated potential enhancement of single-agent activities within the tumor cells, targeting of the marrow micromilieu, or circumvention of drug resistance in t(4;14)+ MM.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BerdelWolfgang EWE,
pubmed-author:BispingGuidoG,
pubmed-author:GustavusDirkD,
pubmed-author:HilbergFrankF,
pubmed-author:KienastJoachimJ,
pubmed-author:KropffMartinM,
pubmed-author:Müller-TidowCarstenC,
pubmed-author:MestersRolf MRM,
pubmed-author:MunzertGerdG,
pubmed-author:RothGerald JGJ,
pubmed-author:StefanicMartinM,
pubmed-author:StelljesMatthiasM,
pubmed-author:VolpertSarahS,
pubmed-author:WenningDorisD
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
520-31
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:19147757-Antineoplastic Agents,
pubmed-meshheading:19147757-Antineoplastic Agents, Hormonal,
pubmed-meshheading:19147757-Boronic Acids,
pubmed-meshheading:19147757-Cell Line, Tumor,
pubmed-meshheading:19147757-Chromosomes, Human, Pair 14,
pubmed-meshheading:19147757-Chromosomes, Human, Pair 4,
pubmed-meshheading:19147757-Dexamethasone,
pubmed-meshheading:19147757-Enzyme Inhibitors,
pubmed-meshheading:19147757-Fibroblast Growth Factor 3,
pubmed-meshheading:19147757-Humans,
pubmed-meshheading:19147757-In Situ Hybridization, Fluorescence,
pubmed-meshheading:19147757-Multiple Myeloma,
pubmed-meshheading:19147757-Mutation,
pubmed-meshheading:19147757-Protein-Tyrosine Kinases,
pubmed-meshheading:19147757-Pyrazines,
pubmed-meshheading:19147757-Translocation, Genetic
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
|
|
pubmed:affiliation |
Department of Medicine/Hematology and Oncology, University of Muenster, Muenster, Germany.
|
|
pubmed:publicationType |
Journal Article
|
